Contribution of Deep Learning in the Investigation of Possible Dual LOX-3 Inhibitors/DPPH Scavengers: The Case of...

Even though non-steroidal anti-inflammatory drugs are the most effective treatment for inflammatory conditions, they have been linked to negative side effects. A promising approach to mitigating potential risks, is the development of new compounds able to combine anti-inflammatory with antioxidant activity to enhance activity and reduce toxicity. The implication of reactive oxygen species in inflammatory conditions has been extensively studied, based on the pro-inflammatory properties of generated free radicals. Drugs with dual activity (i.e., inhibiting inflammation related enzymes, e.g., LOX-3 and scavenging free radicals, e.g., DPPH) could find various therapeutic applications, such as in cardiovascular or neurodegenerating disorders. The challenge we embarked on using deep learning was the creation of appropriate classification and regression models to discriminate pharmacological activity and selectivity as well as to discover future compounds with dual activity prior to synthesis. An accurate filter algorithm was established, based on knowledge from compounds already evaluated in vitro, that can separate compounds with low, moderate or high activity. In this study, we constructed a customized highly effective one dimensional convolutional neural network (CONV1D), with accuracy scores up to 95.2%, that was able to identify dual active compounds, being LOX-3 inhibitors and DPPH scavengers, as an indication of simultaneous anti-inflammatory and antioxidant activity. Additionally, we created a highly accurate regression model that predicted the exact value of effectiveness of a set of recently synthesized compounds with anti-inflammatory activity, scoring a root mean square error value of 0.8. Eventually, we succeeded in observing the manner in which those newly synthesized compounds differentiate from each other, regarding a specific pharmacological target, using deep learning algorithms.